+ Product Pathways
- All Targets
- Angiogenesis/Tyrosine Kinase
- Cell Cycle/Checkpoint
- HDAC
- Apoptosis
- PARP
- Aurora/Ksp
- MAPK
- PI3K/Akt/mTOR
- Hormone
- Integrase/CCR5
- Proteases/HSP90/HSP70
- Wnt/Hedgehog/Notch
- Jak/Stat
- Ca/cAMP/Lipid Signaling
- Neuro Signaling
- TGF-beta/Smad Signaling
- GPCR
- Ion channel
- Cytochrome P450
- Others
- Cancer
- Infection
- Endocrinology
- Metabolic Disease
- Inflammation
- Immunology
- Neurological Disease
- Cardiovascular Disease
Mesenchymal-epithelial transition factor
| Cat.No. | Product Name | Feedback | Added |
|---|---|---|---|
| S1316 | AMG-208 | Jun 2010 | |
| AMG-208 is a potent small molecular c-Met inhibitor with an IC50 of 9.3 nM. | |||
| S1005 | Axitinib |  | Apr 2009 |
| Axitinib is a receptor kinase inhibitor with IC50 of 0.1 nmol (VEGFR-1), 0.2 nmol (VEGFR-2), 0.1–0.3 nmol (VEGFR-3), 1.6 nmol (PDGFR-β) and 1.7 nmol (c-KIT). | |||
| S1561 | BMS 777607 | Nov 2010 | |
| BMS 777607 is a Small-Molecule Met Kinase Inhibitor with an IC50 of < 0.1 μM. | |||
| S1111 | Foretinib (GSK1363089, XL880) | | Sep 2009 |
| Foretinib (GSK1363089, XL880) is a novel MET and VEGFR2/KDR kinases inhibitor with an IC50 of 0.4 and 0.8 nM for MET and KDR, respectively. | |||
| S1114 | JNJ-38877605 | | Sep 2009 |
| JNJ-38877605 is a c-MET inhibitor with an IC50 of 4 nM. | |||
| S1361 | MGCD-265 | | Jun 2010 |
| MGCD-265 is a multi-targeted kinase inhibitor, which targets the c-MET, VEGFR1, VEGFR2, VEGFR3, Tie-2 and Ron receptor tyrosine kinases. | |||
| S1094 | PF-04217903 | | Aug 2009 |
| PF-04217903 is a MET inhibitor with an IC50 from 3.1 nM to142 nM. | |||
| S1068 | PF-2341066(Crizotinib) | | Jun 2009 |
| Inhibitor of the c-Met kinase and the NPM-ALK. PF-2341066 inhibited cell proliferation in ALK-positive ALCL cells (IC50s=30 nM). | |||
| S1070 | PHA-665752 | | Jun 2009 |
| PHA-665752 is c-Met inhibitor with an IC50 of 9 nM and Ki of 4 nM. | |||
| S1112 | SGX-523 | | Sep 2009 |
| SGX-523 is an exquisitely selective, ATP-competitive MET receptor tyrosine kinase inhibitor with an IC50 of 4 nM for the inhibition of HGFR. | |||
| S1080 | SU11274 | | Jul 2009 |
| SU11274 is a c-Met inhibitor (IC50 at 0.012μM). | |||
| S1119 | XL184 (Cabozantinib) | Sep 2009 | |
| XL184 (Cabozantinib) is a potent multitargeted VEGFR2, Met, FLT3, Tie2, Kit and Ret inhibitor with IC50 of 0.035, 1.8, 14.4, 14.3 and 4.6 nM for VEGFR2, Met, FLT3, Tie2 and Kit, respectively. | |||
Buy Now / Print Quote
Find Multiple Products by Catalog Number
Customer's Feedback
| Dongfeng Chen, The Rausing Lab |
| "Your product U0126(Cat.NO S1102) works well in our experiments. I hope I can get more excellent products from your company in future." |
| R.B. Cambridge |
| "I have used the chemical that I bought from you(Selleck,PTC-124) and it worked well.So we will eventually be ordering more." |
| Zhenghe John Wang Assistant Professor, Case Western Reserve University |
| "We have purchased LBH-589, Saha and MS-275 from you and they all worked well." |
| Jenny Sun |
| "We used the LBH-589 in our experiments. The compound is easy to use with excellent reproducibility." |
| Yu Wang, Harvard University |
| "The GDC0449 compound worked very well. The results in my hands are equally good as what's been published. Thanks for this great resource for our research." |
| Dung-Fang Lee |
| "Based on our preliminary data, I found MLN8237 and VX-680 have good effects in inhibiting Aurka-maintaining ESC self-renewal in mouse ES cells." |
Latest Catalog
| May 2010 Selleck Latest Catalog |  |
